Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study

European Journal of Cancer

Volumn 45, Issue 10, 2009, Pages 1788-1797

  Barbare, Jean Claude ^a,b   Bouché, Olivier ^a,c   Bonnetain, Franck ^a,d   Dahan, Laetitia ^a,e   Lombard Bohas, Catherine ^a,f   Faroux, Roger ^a,g   Raoul, Jean Luc ^a,h,i   Cattan, Stéphane ^a,j   Lemoine, Alain ^a,g   Blanc, Jean Frédéric ^a,k   Bronowicki, Jean Pierre ^a,l   Zarski, Jean Pierre ^a,m   Cazorla, Sophie ^a,k   Gargot, Dany ^a,g   Thevenot, Thierry ^a,n   Diaz, Emmanuel ^a,o   Bastie, Anne ^a,p   Aparicio, Thomas ^a,q   Bedenne, Laurent ^a,d  

^a Hôpitaux Généraux   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c CHRU Reims   (France)

^d Chu   (France)

^e TIMONE HOSPITAL   (France)

^f Service d'Hépatogastroentérologie   (France)

^g Service d'Hépatogastroentérologie   (France)

^h CENTRE EUGÈNE MARQUIS   (France)

ⁱ European University in Brittany   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k BORDEAUX UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF NANCY   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^o Service De Gastroentérologie   (France)

^p NOVARTIS PHARMA K K   (Japan)

^q ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

Efficacy; Hepatocellular carcinoma (HCC); Octreotide; Randomised clinical trial; Somatostatin receptors; Tolerability

Indexed keywords

OCTREOTIDE; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEARTBURN; HEMATOMA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67149113508     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.02.018     Document Type: Article

References (23)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. Kew M.C. Hepatocellular cancer. A century of progress. Clin Liver Dis 4 (2000) 257-268
3. Bosch F.X., Ribes J., and Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis 19 (1999) 271-285
4. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
5. Remontet L., Estève J., Bouvier A.M., et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 51 (2003) 3-30
6. Llovet J.M., and Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (2008) 520-537
7. Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med 359 (2008) 378-390
8. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 (2001) 421-430
9. Slooter G.D., Mearadji A., Breeman W.A., et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Brit J Surg 88 (2001) 31-40
10. Lamberts S.W., van der Lely A.J., de Herder W.W., et al. Octreotide. New Engl J Med 334 (1996) 246-254
11. Reubi J.C., Zimmermann A., Jonas S., et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45 (1999) 766-774
12. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. World J Gastroenterol 13 (2007) 3164-3170
13. Kouroumalis E., Skordilis P., Themros K., et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42 (1998) 442-447
14. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31 (2000) 840-845
15. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
16. Yuen M.F., Poon R.T., Lai C.L., et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36 (2002) 687-691
17. Becker G., Allgaier H.P., Olschewski M., Zähringer A., et al., HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45 (2007) 9-15
18. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49 (2002) 1245-1250
19. Samonakis D.N., Moschandreas J., Arnaoutis T., et al. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 9 (2002) 903-907
20. Nguyen-Khac E., Moullart V., Ollivier-Hourman I., et al. Search of somatostatin's receptors in hepatocellular carcinoma by the 111IN-pentetreotide scintigraphy in palliative situation: a French multicentric retrospective study. Gut 55 (2006) A145
21. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
22. Del Poggio P, Mattiello M, Gilardoni L, et al. The mysterious case of spontaneous disappearance of hepatocellular carcinoma. Dig Liver Dis [in press]. doi:10.1016/j.dld.2008.02.001.
23. Del Prete S, Montella L, Addeo R, et al. Sorafenib plus long-acting octreotide in advanced hepatocellular carcinoma. Preliminary results of a multicenter ongoing study. Clin Oncol 2008;26(May 20 suppl; abstr 15624).